Samjot Singh Dhillon

Samjot Singh Dhillon

Auto-generated profile, based on publicly available information

Samjot Singh Dhillon

Pulmonary Critical Care and Sleep Medicine, Interventional Pulmonary, The Permanente Medical Group, Roseville and Sacramento, CA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
JCJoshua D. Campbell
Joshua D. Campbell
SMSarah A. Mazzilli
Sarah A. Mazzilli
MRMary E. Reid
Mary E. Reid
SDSamjot S. Dhillon
Samjot S. Dhillon
SPSuso Platero
Suso Platero
ASAvrum E. Spira
Avrum E. Spira
Understanding the earliest molecular and cellular events associated with cancer initiation remains a key bottleneck to transforming our approach to cancer prevention and detection. While TCGA has provided unprecedented insights into the genomic events associated with advanced stage cancer, there have been few studies comprehensively profiling premalignant and early-stage disease or elucidating the role of the microenvironment in premalignancy and tumor initiation. In this article, we make a call for development of a “Pre-Cancer Genome Atlas (PCGA),” a concerted initiative to characterize the molecular alterations in premalignant lesions and the corresponding changes in the microenvironment associated with progression to invasive carcinoma. This initiative will require a multicenter coordinated effort to comprehensively profile (cellular and molecular) premalignant lesions and their corresponding “field of injury” collected longitudinally as the lesion progresses towards or regresses from frank malignancy across multiple tumor types. Genomic characterization of alterations in premalignant lesions and their microenvironment, for both bulk tissue and single cells, will enable development of biomarkers for early detection and risk stratification as well as allow for the development of novel targeted cancer interception strategies. The multi-institutional and multidisciplinary collaborative “big-data” effort underlying the PCGA will help usher in a new era of precision medicine for cancer detection and prevention. Cancer Prev Res; 9(2); 119–24. ©2016 AACR.

1 March 2017 in Chest
Verified
Journal Article
Closed access
MPMonali Patil
Monali Patil
SDSamjot Singh Dhillon
Samjot Singh Dhillon
KAKristopher Attwood
Kristopher Attwood
MSMarwan Saoud
Marwan Saoud
AAAbdul Hamid Alraiyes
Abdul Hamid Alraiyes
Kassem HarrisKassem Harris
Kassem Harris

1 March 2000 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SDSamjot Singh Dhillon
Samjot Singh Dhillon
CWChatrchai Watanakunakorn
Chatrchai Watanakunakorn
An 81-year-old woman who presented with middle lobe bronchiectasis and Mycobacterium avium complex infection is described. She had a history of habit

1 September 2017 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
SDSamjot Singh Dhillon
Samjot Singh Dhillon
KHKassem Harris
Kassem Harris
Peripheral pulmonary lesions (PPLs) are generally considered as lesions in the peripheral one-third of the lung although a precise definition and radiographic anatomical landmarks separating central and peripheral lesion does not yet exist. The radiographic detection of such lesions has increased significantly with the adoption of lung cancer screening programs. These lesions are not directly visible by regular flexible bronchoscopes as they are usually distal to the lobar and segmental bronchi. Traditionally, depending on location and clinical stage at presentation, these lesions were typically sampled by computerized tomography (CT) guided needle or surgical biopsy although some centers also used ultrasound and fluoroscopy guided percutaneous needle biopsy. Due to lack of direct visualization, the yield for bronchoscopic guided sampling especially of the small <2 cm pulmonary nodules was very low. Therefore, sampling has been preferentially performed by percutaneous CT guidance, which had high yield of above 90% but it comes at the cost of higher risk complications like pneumothorax with reported rate of 15% to 28%. Directly proceeding to surgical resection is also considered in appropriate candidates with high suspicion of malignancy without any evidence of distant metastasis but the proportion of such cases of lung cancer is low. The manuscript discussed the various bronchoscopic diagnostic modalities for peripheral pulmonary lesions. It is important to note that most of the studies in this field are relatively small, not randomized, suffer from selection bias, have considerable heterogeneity in sampling methodology/instruments and usually have been performed in high volume institutions by dedicated highly experienced proceduralists. The prevalence of malignancy in most of the reported cohorts has also been high which may result in higher diagnostic yields. All these factors need to be kept in mind before generalizing the results to individual centers and practices.

1 November 1999 in Chest
Verified
Journal Article
Closed access
SDSamjot Singh Dhillon
Samjot Singh Dhillon
DSDigvijay Singh
Digvijay Singh
NDNathaniel Doe
Nathaniel Doe
AQAlam M. Qadri
Alam M. Qadri
SRSantuccio Ricciardi
Santuccio Ricciardi
MSMarvin I. Schwarz
Marvin I. Schwarz

1 March 2015 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
SPSantosh Patnaik
Santosh Patnaik
RMReema Mallick
Reema Mallick
EKEric Kannisto
Eric Kannisto
RSRohit Sharma
Rohit Sharma
WBWiam Bshara
Wiam Bshara
SDSamjot Singh Dhillon
Samjot Singh Dhillon
Introduction Identification of adenocarcinoma (AC) and squamous cell carcinoma (SCC) histology of non–small-cell lung cancer (NSCLC) in biopsies is clinically important but can be inaccurate by routine histopathologic examination. We quantify this inaccuracy at a cancer center, and evaluate the utility of a microRNA-based method to histotype AC/SCC in biopsies. Methods RNA was extracted from tissue sections with greater than 90% tumor content that were macro- or micro-dissected from formalin-fixed, paraffin-embedded biopsy specimens. MicroRNAs in RNA from the biopsies and from resected tumors were quantified by TaqMan reverse transcription-polymerase chain reaction assays and normalized against the RNU6B housekeeping RNA. Publicly available microRNA expression datasets were examined. Results NSCLC subtyping of small biopsy specimens by routine histopathologic examination either failed or mistyped the histology of 21% of 190 cases. Using 77 resectates, an reverse transcription-polymerase chain reaction-based assay of microRNAs miR-21, miR-205, and miR-375 was developed to identify AC and SCC subtypes of NSCLC. This method identified the AC/SCC histotypes of 25 biopsies with an accuracy of 96%, and correctly histotyped all 12 cases for which the histology had been mistyped by routine histopathologic examination of the biopsy. Examination of publicly available datasets identified miR-205 and miR-375 as microRNAs with the best ability to histotype AC and SCC, and that levels of the two microRNAs in AC or SCC are unaffected by the pathologic stage of the tumor or the age or race of the patient. Conclusions Histotypic microRNA assays can aid the subtyping of NSCLC biopsies as AC or SCC by standard histopathologic methods.